NVAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the data provided, Novavax (NVAX) does not present a strong buy opportunity for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. While the company has shown significant revenue growth and optimism around its partnerships, the financial performance is mixed, with declining net income and EPS. Additionally, the technical indicators suggest the stock is overbought, and there are no strong proprietary trading signals or significant positive catalysts to justify an immediate buy.
The technical indicators show a mixed picture. The MACD is positive and expanding, suggesting bullish momentum. The RSI is at 90.418, indicating the stock is overbought. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading close to resistance levels (R1: 11.242, R2: 12.12). This suggests limited upside potential in the short term.
Revenue increased by 67% YoY in Q4 2025, driven by partnerships and R&D.
Raised adjusted revenue forecast for
Optimism around flu vaccine development inspired by Moderna's advancements.
Net income dropped by 121.63% YoY in Q4
EPS declined by 117.65% YoY.
Analysts maintain Hold or Underperform ratings with limited upside in price targets.
RSI indicates the stock is overbought, suggesting potential for a pullback.
In Q4 2025, revenue increased by 66.61% YoY to $147 million, and gross margin improved by 43.94% YoY to 84.98%. However, net income dropped by 121.63% YoY to $17.53 million, and EPS declined by 117.65% YoY to $0.09, reflecting profitability challenges.
Analysts have mixed views. TD Cowen raised the price target to $8 from $7 with a Hold rating, while BofA raised the price target to $7 from $6 but reiterated an Underperform rating. Analysts are cautious about the company's licensing agreements and development timelines.
